| RE46276 |
Triazolo(4,5-D)pyrimidine compounds |
David Hardem, Anthony Ingall, Paul Willis, Simon Guile |
2017-01-17 |
|
| 8314127 |
Piperidine derivatives |
Talbir Austin, David O'Sullivan, Matthew Perry |
2012-11-20 |
$16,825,000 |
| 7709500 |
Chemical compounds |
Lilian Alcaraz, Mark Furber, Mark Purdie |
2010-05-04 |
$3,255,000 |
| 7517989 |
Piperidine derivatives useful as modulators of chemokine receptor activity |
Christopher A. Luckhurst, Matthew Perry, Hitesh Sanganee |
2009-04-14 |
$16,393,000 |
| 7495013 |
Chemical compounds |
Moya Caffrey, Christopher A. Luckhurst, Tobias Mochel, Matthew Perry |
2009-02-24 |
$25,838,000 |
| 7482363 |
Piperidine derivatives useful as modulators of chemokine receptor activity |
Hitesh Sanganee |
2009-01-27 |
$8,249,000 |
| 7348341 |
Chemical compounds |
Hitesh Sanganee |
2008-03-25 |
$8,741,000 |
| 7307090 |
Piperidine derivatives useful as modulators of chemokine receptor activity |
Richard Evans, Matthew Perry |
2007-12-11 |
$9,456,000 |
| 7304077 |
Chemical compounds |
Hitesh Sanganee |
2007-12-04 |
$8,303,000 |
| 7265227 |
Piperidine derivatives useful as modulators of chemokine receptor activity |
Richard Evans, Matthew Perry |
2007-09-04 |
$7,893,000 |
| 7250419 |
Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
David Hardern, Anthony Ingall, Paul Willis, Simon Guile |
2007-07-31 |
$36,849,000 |
| 7238691 |
Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity |
Hitesh Sanganee |
2007-07-03 |
$9,606,000 |
| 7238811 |
Chemical compounds |
Aaron Rigby, Hitesh Sanganee, Louise Lawrence |
2007-07-03 |
$9,606,000 |
| 7179922 |
Chemical compounds |
Aaron Rigby, Hitesh Sanganee, Louise Lawrence |
2007-02-20 |
$21,281,000 |
| 7034032 |
Cyclopentan-2-ol-1-yl-[1,2,3]triazolo[4,5-D]pyrimidine compounds |
Roger Brown, Simon Guile, Garry Pairaudeau |
2006-04-25 |
$19,937,000 |
| 6974868 |
Compounds |
David Hardern, Anthony Ingall, Paul Willis, Simon Guile |
2005-12-13 |
$11,892,000 |
| 6958350 |
Chemical compounds |
Stephen Brough, Thomas McInally, Matthew Perry |
2005-10-25 |
$12,058,000 |
| 6903115 |
Bipiperidine compounds |
Aaron Rigby, Hitesh Sanganee, Louise Lawrence |
2005-06-07 |
$11,041,000 |
| 6903085 |
Substituted piperidine compounds useful as modulators of chemokine receptor activity |
Stephen Thom, Andrew Baxter, Nicholas Kindor, Thomas McInally, Matthew Perry +3 more |
2005-06-07 |
$11,041,000 |
| 6713483 |
[1,2,3]-triazolo[4,5-d] pyrimidine compounds |
Simon Guile |
2004-03-30 |
$35,813,000 |
| 6525060 |
Triazolo(4,5-d)pyrimidine compounds |
David Hardern, Anthony Ingall, Paul Willis, Simon Guile |
2003-02-25 |
$5,431,000 |
| 6525070 |
Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists |
Aaron Rigby, Hitesh Sanganee, Louise Lawrence |
2003-02-25 |
$5,431,000 |
| 6369064 |
Triazolo(4,5-d)pyrimidine compounds |
Roger Brown, Garry Pairaudeau, Stephen Thom, Paul Willis |
2002-04-09 |
$7,882,000 |
| 6297232 |
Triazolo[4,5-D]pyrimidinyl derivatives and their use as medicaments |
Roger Bonnert, Anthony Ingall, Paul Willis |
2001-10-02 |
$30,815,000 |
| 6251910 |
1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Simon Guile, Anthony Ingall, Paul Willis |
2001-06-26 |
$10,685,000 |
